Retrieve available abstracts of 38 articles: HTML format
Single Articles
March 2025
BANERJEE SS, Sahai S, Chate GP Guillain-Barre syndrome outbreak in Pune: a health emergency.
Lancet. 2025 Mar 21:S0140-6736(25)00414-3. doi: 10.1016/S0140-6736(25)00414. PubMed
LATEEF S India faces major Guillain-Barre syndrome epidemic.
Lancet. 2025;405:769. PubMed
January 2025
ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis
(ADJUST): a multicentre, double-masked, randomised controlled trial.
Lancet. 2025;405:303-313. PubMedAbstract available
BENHADOU F, Cogan E Targeting IFNbeta in dermatomyositis.
Lancet. 2025;405:99-101. PubMed
FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific
monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind,
randomised, placebo-controlled, phase 2 trial.
Lancet. 2025;405:137-146. PubMedAbstract available
November 2024
DE FREMONT GM, Lenfant T, Le Guern V, Costedoat-Chalumeau N, et al Therapies for systemic lupus erythematosus.
Lancet. 2024;404:2163. PubMed
MATUCHANSKY C Therapies for systemic lupus erythematosus.
Lancet. 2024;404:2163. PubMed
HOI A, Igel T, Mok CC, Arnaud L, et al Therapies for systemic lupus erythematosus - Authors' reply.
Lancet. 2024;404:2163-2164. PubMed
XU Q Therapies for systemic lupus erythematosus.
Lancet. 2024;404:2162. PubMed
PABST T, Maurer B Therapies for systemic lupus erythematosus.
Lancet. 2024;404:2162. PubMed
HAGEN M, Muller F, Wirsching A, Kharboutli S, et al Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.
Lancet. 2024;404:2158-2160. PubMed
September 2024
LOVE KM, Brown SA The promise of once-weekly insulins for type 1 diabetes: update on progress.
Lancet. 2024;404:1081-1083. PubMed
BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults
with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
Lancet. 2024;404:1132-1142. PubMedAbstract available
August 2024
AL-SAMKARI H, B Bussel J, Miyakawa Y, Broome CM, et al Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors'
reply.
Lancet. 2024;404:434. PubMed
JACOBS JW, Booth GS, Stephens LD, Tormey CA, et al Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
Lancet. 2024;404:433. PubMed
MA RW, Liu K, Xie J Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
Lancet. 2024;404:433-434. PubMed
July 2024
SCHETT G, Mackensen A, Mougiakakos D CAR T-cell perspectives in lupus - Authors' reply.
Lancet. 2024;404:336-337. PubMed
GREMESE E, Bruno D, Ferraccioli G CAR T-cell perspectives in lupus.
Lancet. 2024;404:336. PubMed
June 2024
LAFAYETTE R, Kristensen J, Stone A, Barratt J, et al Targeted release of budesonide in primary IgA nephropathy - Authors' reply.
Lancet. 2024;403:2786. PubMed
ZOU Y, Du X, Zou J Targeted release of budesonide in primary IgA nephropathy.
Lancet. 2024;403:2785-2786. PubMed
HU Y, Zhang Y Targeted release of budesonide in primary IgA nephropathy.
Lancet. 2024;403:2785. PubMed
SAKUMA I, Ishibashi R, Matsue K, Vatner DF, et al Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old
man.
Lancet. 2024;403:e33. PubMed
April 2024
HOI A, Igel T, Mok CC, Arnaud L, et al Systemic lupus erythematosus.
Lancet. 2024 Apr 17:S0140-6736(24)00398-2. doi: 10.1016/S0140-6736(24)00398. PubMedAbstract available
KRICKAU T, Naumann-Bartsch N, Aigner M, Kharboutli S, et al CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis
from haemodialysis.
Lancet. 2024 Apr 17:S0140-6736(24)00424-0. doi: 10.1016/S0140-6736(24)00424. PubMed
February 2024
KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al Diagnosis and management of ANCA-associated vasculitis.
Lancet. 2024;403:683-698. PubMedAbstract available
VAN DER HELM-VAN MIL AHM Abatacept in individuals with autoantibody-positive arthralgia at risk for
rheumatoid arthritis.
Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055. PubMed
January 2024
WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al Complement in human disease: approved and up-and-coming therapeutics.
Lancet. 2024;403:392-405. PubMedAbstract available
CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al Hyperthyroidism.
Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016. PubMedAbstract available
November 2023
JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al Multiple sclerosis.
Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473. PubMedAbstract available
REICH HN, Barbour SJ PROTECTing the kidneys in IgA nephropathy.
Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418. PubMed
ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al Efficacy and safety of sparsentan versus irbesartan in patients with IgA
nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase
3 trial.
Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302. PubMedAbstract available
SINGH M, Wambua S, Lee SI, Okoth K, et al Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
Lancet. 2023;402 Suppl 1:S84. PubMedAbstract available
October 2023
ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al Polymyalgia rheumatica.
Lancet. 2023;402:1459-1472. PubMedAbstract available
RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al Once-weekly insulin icodec versus once-daily insulin degludec as part of a
basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a,
randomised, open-label, treat-to-target trial.
Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179. PubMedAbstract available
SHAH AS, Wolf RM Weekly insulin: a paradigm shift in type 1 diabetes therapy.
Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227. PubMed
September 2023
BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults
with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised,
placebo-controlled, phase 3 trial.
Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460. PubMedAbstract available
MAHAMAD S, Arnold DM Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836. PubMed
SCHETT G, Mackensen A, Mougiakakos D CAR T-cell therapy in autoimmune diseases.
Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126. PubMedAbstract available